Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
about
The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysisA critical evaluation of the therapeutic range of indinavir.Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.Candida albicans secreted aspartyl proteinases in virulence and pathogenesisPharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant womenPharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers.Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant womenPharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.Pharmacokinetic optimization of antiretroviral therapy in pregnancy.Sequence-specific alterations of epitope production by HIV protease inhibitors.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.International interlaboratory quality control program for measurement of antiretroviral drugs in plasma.HIV Protease Inhibitor-Induced Cathepsin Modulation Alters Antigen Processing and Cross-PresentationSteady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.Ritonavir and Saquinavir directly stimulate anterior pituitary prolactin secretion, in vitro.Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.Pharmacokinetic properties of indinavir in rat: some limitations of noncompartmental analysis.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women.Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients.Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects.Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy.
P2860
Q33714126-4397FA1F-0F93-4E6E-885D-3F120311FC26Q34312147-147D1AB2-09C9-4B69-B529-99A478107044Q34709881-E226E38F-3EBF-48B2-A18B-468CB8E406B9Q35013781-311FEDBA-1627-4FB1-85BA-36272DDCBB81Q35215948-3AA07D87-F39B-4749-9889-BAF5D3AFF270Q35547832-3164F703-B130-456D-B7FC-D3D886501C3DQ35557216-7E52D463-3C76-4D51-A9C9-DBACC45CC6A7Q35846675-7E10A52A-E59B-4151-B5C9-D2E41F974741Q36723780-6F3119D8-00A7-4CAE-89C1-7A63A45A9BF8Q36803454-CC6E7B1E-020A-4D8D-B2F6-DA003D3A3F61Q37734814-159A484F-E0A0-4B01-9837-9F7A51B9A422Q38047214-CE235B23-5221-4D19-B07D-EF77AD295C1EQ38710071-492BC18D-828D-44C8-8BF8-B6414DC62C2FQ38954109-0E9A308D-07E6-4420-BB40-5FCA3FD52E7CQ38980548-87057C03-AD1E-4323-8752-53277F795072Q39652990-9157F9C7-0655-40B2-B0C1-6BCD7F0AB4F1Q40743173-BEC4C6D4-53FE-46A3-A9CE-EFFC953072CAQ41842301-88466069-CBF4-49F4-A426-7F6AD7479ADEQ42437257-5BB31381-0CA3-4607-8800-1C20ABFC6139Q42625394-0CADB9F7-B55F-4F53-8D5A-B9CFA74FCC36Q43282509-4D25204F-F478-4B22-A05D-2E7C93FCB97CQ43818117-66D2ED59-D940-4947-B508-08EAFED45CB1Q43822045-489B23F3-301A-4B58-9ABE-919B0F0B6B8CQ43871660-673AE13F-0A30-49AC-BE78-010325C13243Q44202500-7FF2607B-0FE0-4730-92D2-13374A54EBD5Q46562540-7A75652D-971D-47F9-A26C-45EDAC97CC31Q46582815-F067301A-26D5-485E-A3EE-A9DE1AF9D15CQ47135424-F5934E82-D21B-425C-90BD-4464C4C87B10
P2860
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
@ast
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
@en
type
label
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
@ast
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
@en
prefLabel
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
@ast
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
@en
P2093
P2860
P356
P1476
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
@en
P2093
C V Fletcher
E P Acosta
P L Anderson
R C Brundage
T N Kakuda
P2860
P304
P356
10.1086/313852
P407
P478
30 Suppl 2
P577
2000-06-01T00:00:00Z